UCB S.A. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
160,000.00
209,000.00
264,000.00
520,000.00
753,000.00
800
Depreciation, Depletion & Amortization
238,000.00
220,000.00
252,000.00
232,000.00
234,000.00
288
Other Funds
104,000.00
183,000.00
372,000.00
419,000.00
384,000.00
49
Funds from Operations
294,000.00
48,000.00
120,000.00
248,000.00
837,000.00
1,094
Changes in Working Capital
128,000.00
380,000.00
35,000.00
100,000.00
37,000.00
68
Net Operating Cash Flow
166,000.00
428,000.00
155,000.00
348,000.00
874,000.00
1,026
Capital Expenditures
344,000.00
161,000.00
146,000.00
138,000.00
209,000.00
Sale of Fixed Assets & Businesses
55,000.00
11,000.00
989,000.00
453,000.00
2,000.00
Purchase/Sale of Investments
1,000.00
21,000.00
7,000.00
-
14,000.00
Net Investing Cash Flow
288,000.00
161,000.00
889,000.00
317,000.00
228,000.00
Cash Dividends Paid - Total
205,000.00
222,000.00
225,000.00
231,000.00
217,000.00
Issuance/Reduction of Debt, Net
685,000.00
241,000.00
80,000.00
908,000.00
6,000.00
Net Financing Cash Flow
554,000.00
516,000.00
267,000.00
1,188,000.00
328,000.00
Net Change in Cash
429,000.00
243,000.00
778,000.00
521,000.00
287,000.00
Free Cash Flow
72,000.00
344,000.00
84,000.00
240,000.00
774,000.00
Deferred Taxes & Investment Tax Credit
-
198,000.00
24,000.00
85,000.00
234,000.00
55
Net Assets from Acquisitions
-
-
2,000.00
-
7,000.00
Other Sources
-
10,000.00
41,000.00
2,000.00
-
Change in Capital Stock
74,000.00
53,000.00
122,000.00
49,000.00
105,000.00
Exchange Rate Effect
3,000.00
6,000.00
1,000.00
2,000.00
31,000.00

About UCB

View Profile
Address
Allée de la Recherche, 60
Brussels BU 1070
Belgium
Employees -
Website http://www.ucb.com
Updated 07/08/2019
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.